Prexton begins Phase II trial of Foliglurax to treat Parkinson ’s disease

Swiss biopharmaceutical firm Prexton Therapeutics has begun a Phase II clinical trial (AMBLED) of Foliglurax for the treatment of patients suffering with Parkinson ’s disease (PD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news